MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China
MediciNova, Inc. (MNOV)
Last medicinova, inc. earnings: 4/23 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
medicinova.com/investor-relations/media-archive
Company Research
Source: GlobeNewswire
LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Chinese Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis. The allowed claims also cover the inhibition of pulmonary scarring, the reduction or inhibition of elevated lung hydroxyproline levels, the reduction of elevated lung density, and the reduction of elevated total cell count in bronchoalveolar lavage fluid using MN-001. The allowed claims cover oral administration, including table
Show less
Read more
Impact Snapshot
Event Time:
MNOV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNOV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNOV alerts
High impacting MediciNova, Inc. news events
Weekly update
A roundup of the hottest topics
MNOV
News
- Innovative Advances in Alcohol Use Disorder Therapeutics Report 2024: In-depth Insights on 30+ Companies and 30+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to StockholdersGlobeNewswire
- MediciNova, Inc. (NASDAQ: MNOV) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver [Yahoo! Finance]Yahoo! Finance
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the LiverGlobeNewswire
MNOV
Earnings
- 11/13/24 - In-Line
MNOV
Sec Filings
- 11/13/24 - Form 10-Q
- MNOV's page on the SEC website